Historical Development – Some Milestones.
| 1987–1990s | Dromex was founded in 1990; however, the company owners had started to do some ‘spot’ businesses together since 1987. Diversification into manufacturing; looking to diversify and reduce risk, the Dromex partners also decided to expand from purely commercial activity into manufacturing. |
| 1990 | In the late 1990s, with enormous efforts, the company bought a freeze-dry (lyophilisation) old plant in Buenos Aires, named Instituto Biologico Contemporaneo (IBC), to formulate lyophilised finished products for third parties. Dromex would supply API to their customers and formulate for them through Dromex’ subsidiary IBC, acting as a contractor. |
| 1998 | The 3 friends/partners joined the business. The IBC plant in Buenos Aires was remodelled and updated, exceeding the norms and existing regulations of the time, knowing that standards may become more stringent. All this represented an investment of USD 5 million in cash and bank loans. |
| Early 2000s | As IBC became more efficient and ordered, the operation became profitable. Therefore, the partners escalated their commitment to the business by acquiring two further turnkey pharmaceutical injectable plants on the outskirts of Buenos Aires. With those, IBC became a significant player in the Latin American injectable and lyophilisation business and a leading contractor for commercial laboratories. |
| 2008s | In 2008 Drugmex, with a Pharmaceutical plant of 3,900 m2, was started, with production lines of freeze-dried sterile and high-tech injectable solutions, and an estimated capacity of 7 million freeze-dried vials per year and 6 million injectable solutions per year. |
| 2016 | Drugmex officially opened its plant in Queretaro, a strategic location in the central part of Mexico, about 135 miles (220 km) northwest of Mexico City. |
| 2023 | The company has roughly 300 employees as of July 2023 and is now at a crossroads as regards, selling the business or being taken over by the next generation. |
| 1987–1990s | Dromex was founded in 1990; however, the company owners had started to do some ‘spot’ businesses together since 1987. Diversification into manufacturing; looking to diversify and reduce risk, the Dromex partners also decided to expand from purely commercial activity into manufacturing. |
| 1990 | In the late 1990s, with enormous efforts, the company bought a freeze-dry (lyophilisation) old plant in Buenos Aires, named Instituto Biologico Contemporaneo (IBC), to formulate lyophilised finished products for third parties. Dromex would supply API to their customers and formulate for them through Dromex’ subsidiary IBC, acting as a contractor. |
| 1998 | The 3 friends/partners joined the business. The IBC plant in Buenos Aires was remodelled and updated, exceeding the norms and existing regulations of the time, knowing that standards may become more stringent. All this represented an investment of USD 5 million in cash and bank loans. |
| Early 2000s | As IBC became more efficient and ordered, the operation became profitable. Therefore, the partners escalated their commitment to the business by acquiring two further turnkey pharmaceutical injectable plants on the outskirts of Buenos Aires. With those, IBC became a significant player in the Latin American injectable and lyophilisation business and a leading contractor for commercial laboratories. |
| 2008s | In 2008 Drugmex, with a Pharmaceutical plant of 3,900 m2, was started, with production lines of freeze-dried sterile and high-tech injectable solutions, and an estimated capacity of 7 million freeze-dried vials per year and 6 million injectable solutions per year. |
| 2016 | Drugmex officially opened its plant in Queretaro, a strategic location in the central part of Mexico, about 135 miles (220 km) northwest of Mexico City. |
| 2023 | The company has roughly 300 employees as of July 2023 and is now at a crossroads as regards, selling the business or being taken over by the next generation. |
Sharing content requires targeting cookies to be enabled. Please update your cookie preferences to use this feature.